Jonathan specialises in complex and strategically significant intellectual property and technology disputes, with a particular focus on the life sciences and healthcare sectors. He advises clients on regulatory issues and disputes, including therapeutic goods approval, advertising, promotion, and reimbursement of medicines and medical devices. He successfully acted for Hospira and Pfizer in a novel administrative law challenge in the AAT concerning the first biosimilar product to be listed on the PBS following changes to the regulatory and reimbursement regime for biosimilars in Australia, following a section 60 appeal lodged by a third party. He has advised on a number of other novel and nuanced regulatory issues for pharmaceutical and medical device clients. With over 20 years of experience, Jonathan has also represented clients in High Court, Federal Court, and Supreme Court litigation involving breach of contract, copyright, patents, trade marks, misuse of confidential information, misleading and deceptive conduct, and breach of director’s duties. He also advises private and public sector clients on strategies for protecting and enforcing their IP rights.